Our company is committed to the “bench to bedside” translation of research, from the systemic evaluation of mechanisms of therapy resistance to the development of novel therapeutics to treat cancers.
The Unmet Needs of Oncology
250,000 patients are living today with metastatic breast cancer. 42,000 will die within the next 12 months.
239,000 patients are living today with ovarian cancer. 95,000 will die within the next 12 months.
447,000 patients are living today with pancreatic cancer. 357,600 will die within the next 12 months.
250,000 patients are living today with glioblastoma. 200,000 will die within the next 12 months.
694,600 patients will die within the next 12 months because of unmet needs in Oncology.
At etiraRX, we are dedicated to delivering novel therapeutics to treat these needs, and ultimately bridge the gap between previously untreatable cancers and the treatments patients deserve.
Find out how close etiraRX programs are to the finish line
We treat the untreatable.
See the effects of ERX-41 on solid tumors in a newly published paper in Nature Cancer from the lab of etiraRx founder Ganesh Raj.Partner with Us